RNA-based diagnostic algorithms are already clinically validated and changing standard of care. Tests like Oncotype DX (16 RNA biomarkers by PCR), Decipher Prostate, and Afirma have validated that reading RNA from tumor tissue can guide treatment decisions — but each addresses only one clinical question with a small panel.

More than 350,000 RNA algorithms, as reported in the literature, remain unused and have never reached the clinic.

The traditional workflow requires re-engineering any discovered algorithm to a lower-resolution platform — years of work, millions of dollars — and then re-validating from scratch. That is the step that kills 350,000 algorithms.

Because OneRNA® is itself a quantitative, whole-transcriptome RNA-seq platform — the same modality where algorithms were originally discovered — any published RNA algorithm can be uploaded and deployed directly, without years of re-validation.

OneRNA® is different from these first-generation RNA algorithms because it connects directly to treatment options beyond yes/no binary decisions to one treatment